European Research Consortium To Create New Vaccine for Hepatitis C

Joint project HCVAX includes university and corporate research teams from Germany, France and Switzerland
Current treatments for Hepatitis C are expensive and have severe side effects. Approximately 3% of the European population has been affected by the virus. The researchers plan to use biocompatible nanogels as novel drug amplifiers, targeting virus Hepatitis C more effectively and with minimal side effects to the patient. Funding for the project is coming from the European Union’s EuroNanoMed Joint Transnational Initiative.

↑ Back to TechConnect News™

Event Spotlights

Austin, TX, December 1-3, 2015
Austin, TX, December 1-3, 2015

Annual Meeting

TechConnect World 2015
Washington, DC, May 22-25, 2016